Ipamorelin vs Hexarelin

Side effect profile. Hexarelin produces significant cortisol and prolactin elevation at therapeutic doses - not catastrophic but enough to make long-term use uncomfortable and metabolically counterproductive. Ipamorelin was engineered to hit the ghrelin receptor without the collateral effects, and at normal doses it essentially achieves that. When anti-aging and HRT clinics built growth hormone peptide menus in the 2010s, ipamorelin became the default GHRP because it was cleaner. Hexarelin stayed in use mostly for specific research applications.

Yes, the desensitization is well-documented. Published research on hexarelin shows 40-50% reductions in GH response after 8-12 weeks of continuous use, attributed to ghrelin receptor downregulation and reduced pituitary responsiveness. This is why hexarelin protocols historically cycled - typically 4-6 weeks on, equal time off - to preserve sensitivity. Ipamorelin has less documented desensitization, though no GHRP is completely free of tachyphylaxis with chronic use.

Hexarelin activates CD36, a fatty acid transporter receptor expressed on cardiomyocytes, independent of its action on the growth hormone secretagogue receptor. Animal research in cardiac injury models has shown hexarelin reduces ischemia-reperfusion damage and preserves cardiomyocyte function through this pathway. Ipamorelin does not share the CD36 activity. The cardioprotective effect is genuinely interesting and is why hexarelin still shows up in research literature, but it has not advanced to human trials for cardiac indications.

No. Both hexarelin and ipamorelin hit FDA Category 2 in September 2023, which removed the only legitimate 503A compounding pathway that existed for them. Both sit on the February 2026 pending reclassification review, but no regulatory change has taken effect. Research chemical suppliers sell them labeled not for human consumption, which is the legal fiction keeping the underground market running. Legitimate anti-aging clinics that used to prescribe ipamorelin have had to pivot to sermorelin and tesamorelin as their GH-axis options.

Ipamorelin works via Selective growth hormone secretagogue that binds to ghrelin receptors to stimulate GH. Hexarelin works via Potent growth hormone secretagogue with cardioprotective properties beyond GH stimulation. They differ in FDA approval status, efficacy data, and cost.

Ipamorelin typically costs $35 - $70/mo, while Hexarelin costs $40 - $80/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.

Ipamorelin is not FDA-approved (Category 2 (pending reclassification)). Hexarelin is not FDA-approved (Not submitted). FDA approval indicates the treatment has met rigorous safety and efficacy standards.

Common side effects of Ipamorelin include Injection site reactions, Increased hunger, Headache. Common side effects of Hexarelin include Increased appetite, Cortisol elevation, Prolactin elevation. Always consult a healthcare provider about potential side effects.

Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.